Table 3.
The efficiency and side effects of each drug based on the existing data.
| Drugs | efficiency | side effects | |
|---|---|---|---|
| mTOR’s | The graft rejection rate in those treated with sirolimus is 22.2% (2/9). | Not mentioned. | |
| The graft rejection rate in those treated with everolimus is 50.0% (1/2). | |||
| TKI’s | 81.5% (22/27) patients use TKI’s and most of them change to ICI’s due to disease progression. | Proteinuria (44); Nausea, Emesis (41) | |
| ICI’s | PD-1 inhibitors | 28.5% (4/14) patients with disease control. | Graft rejection; Abnormal liver function (38) |
| PD-L1 inhibitors | 0% (0/2) patients with disease control. | ||
| CTLA-4 inhibitors | 100% (1/1) patients with disease control. | ||
| combination therapy (PD-1 inhibitors +PD-L1 inhibitors) | 100% (1/1) patients with disease control. | ||
mTOR, mammalian target of rapamycin; TKI, Tyrosine kinase inhibitors; ICI, immune checkpoint inhibitors; PD-1, programmed cell death protein-1; PD-L1, programmed cell death ligand 1; CTLA-4, cytotoxic T lymphocyte antigen 4.